Truemed Group LLC
- Manufacturer
- Truemed Group LLC
- Effective date
- 2022-08-11
- Label type
- HUMAN PRESCRIPTION DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-05-31 20:43:45
Label at a glance#
ProductTruemed Group LLC
Active ingredientHYDROCHLOROTHIAZIDE, TELMISARTAN
Label structure1 sections
Label contents#
Full prescribing information#
DailyMed RxNorm Mappings#
DailyMed Pharmacologic Classes#
| Class | Version | Type | Effective |
|---|---|---|---|
| HYDROCHLOROTHIAZIDE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| TELMISARTAN Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 82922-037-01 | 2024-01-30 | C162847 | 48780-1 | 1030e365-4844-111a-e063-dadaa90a10e2 | TELMISARTAN HYDROCHLOROTHIAZIDE |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 82922-037-01 | Truemed Group LLC | 14 in 1 BLISTER PACK | TABLET | 14 | 1 |
DailyMed Dashboard NDC Coverage#
Products#
Every source-derived product name is available through these pages.
- Truemed Group LLC
- TELMISARTAN-HYDROCHLOROTHIAZIDE
- HYDROCHLOROTHIAZIDE
- TELMISARTAN
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 82922-037 | 82922-037-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| HYDROCHLOROTHIAZIDE | 0J48LPH2TH | ACTIB |
| TELMISARTAN | U5SYW473RQ | ACTIB |
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| e5fb55b6-5cdd-b9ed-e053-2995a90a37c3 | e5fb55b6-5cdc-b9ed-e053-2995a90a37c3 | 2022-08-11 | e5fb55b6-5cdd-b9ed-e053-2995a90a37c3 e5fb55b6-5cdc-b9ed-e053-2995a90a37c3 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
